Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment

GBI Research, April 2012, Pages: 124

GBI Research, the leading business intelligence provider, has released its latest research “Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment”, which provides insights into the CNS orphan disease therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of amyotrophic lateral sclerosis, huntington’s disease and myasthenia gravis. It also provides the share of generics in global CNS orphan disease therapeutics and in each indication market. The report examines the global orphan diseases therapeutics in CNS usage patterns. It includes the geographical distribution of amyotrophic lateral sclerosis, huntington’s disease and myasthenia gravis markets across the US, the top five countries of Europe and in Japan. The report also includes insights into the orphan diseases therapeutics in CNS Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the CNS orphan disease therapeutics market. Finally, the report includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in the orphan diseases therapeutics in CNS market.

GBI Research’s analysis shows that the overall global CNS orphan disease market is set to increase over the forecast period. It grew from $359.6m in 2002 to $665.5m in 2010 at a Compound Annual Growth Rate (CAGR) of 8%. This is projected to increase to a CAGR of 17.6% over the forecast period to $2.1 billion in 2017. The global ALS therapeutics market generated approximately $163.2m in 2010, growing from $109.7m in 2002 at a CAGR of 5.1%. By 2017, this is expected to have increased to $210.5m at a CAGR of 3.7%. ALS was one of the biggest orphan CNS disease markets globally in 2010. The global HD therapeutics market generated approximately $126.7m in 2010, growing from $34.3m in 2002 at a CAGR of 17.8%. By 2017, this is expected to have increased to $786.5m at a CAGR of 29.8%. Globally, the MG therapeutics market increased from $42.5m in 2002 to $57.7m in 2010 at a CAGR of 3.9%. Over the forecast period it is expected to grow to $88.6m in 2017 with a higher CAGR of 6.3%.

Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global orphan diseases therapeutics in CNS market for three indications, amyotrophic lateral sclerosis, huntington’s disease and myasthenia gravis.
- Data and analysis on the orphan diseases therapeutics in CNS market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain and Japan.
- Annualized market data for the orphan diseases therapeutics in CNS market from 2004 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in global orphan diseases therapeutics in CNS market and for the market of each indication that is covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global market including top companies benchmarking. The key companies studied in this report are Biogen Idec, Avanir Pharmaceuticals, Neuraltus Pharmaceuticals, Cytokinetics, The Avicena Group, NeuroSearch, Trophos, Amarin Corporation, Siena Biotech, Sanofi.
- Key M&A activities and licensing agreements that took place between 2004 and 2011 in the orphan diseases therapeutics in CNS market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Create a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1.1 List of Tables
1.2 List of Figures

2 Orphan Diseases Therapeutics in CNS - Introduction
2.1 GBI Research Report Guidance

3 Orphan Diseases Therapeutics in CNS - Market Overview
3.1 Introduction
3.2 Orphan Disease Regulation and Incentives
3.3 Global Revenue Forecasts for Orphan Diseases Therapeutics in CNS
3.3.1 Global Revenue and Forecast
3.3.2 Geographical Segmentation
3.3.3 Branded and Generic Market Share
3.3.4 Revenue Share by Indication
3.3.5 Market Drivers
3.3.6 Market Restraints
3.3.7 Unmet Needs
3.3.8 Opportunities

4 Orphan Diseases Therapeutics in CNS - Geographical Landscape
4.1 The US
4.1.1 Revenue
4.2 Top Five Countries of Europe
4.2.1 Revenue
4.3 Japan
4.3.1 Revenue

5 Orphan Diseases in CNS Disorders - Therapeutic Landscape
5.1 Amyotrophic Lateral Sclerosis
5.1.1 Disease Overview
5.1.2 Revenue
5.1.3 Average Annual Cost of Treatment
5.1.4 Branded and Generic Market Share
5.1.5 Treatment Algorithm
5.1.6 Treatment Usage Patterns
5.1.7 Approved Molecules
5.1.8 Rilutek
5.1.9 Nuedexta (Dextromethorphan Hydrobromide and Quinidine Sulfate)
5.2 Huntington’s Disease
5.2.1 Disease Overview
5.2.2 Total Revenue
5.2.3 Average Annual Cost of Treatment (ACT)
5.2.4 Branded and Generic Market Share
5.2.5 Treatment Algorithm
5.2.6 Treatment Usage Patterns
5.3 Approved Molecules
5.3.1 Xenazine (tetrabenazine)
5.4 Myasthenia Gravis
5.4.1 Disease Overview
5.4.2 Total Revenue
5.4.3 Branded and Generic Market Share
5.4.4 Average Annual Cost of Treatment
5.4.5 Treatment Algorithm
5.4.6 Treatment Usage Patterns
5.4.7 Approved Molecules
5.5 Other Indications
5.5.1 Total Revenue
5.5.2 Product Profiles

6 Global Orphan Diseases in CNS Disorders - Pipeline Analysis
6.1 Introduction
6.2 Research and Development Pipeline
6.2.1 Overview
6.2.2 Pipeline by Clinical Phases of Development
6.2.3 Profiles of Promising Drugs in Orphan Diseases in CNS Disorders

7 Global Orphan Diseases in CNS Disorders - Competitive Landscape
7.1 Major Players
7.2 Major Company Profiles
7.2.1 Biogen Idec
7.2.2 Avanir
7.2.3 Neuraltus
7.2.4 Cytokinetics
7.2.5 Avicena
7.2.6 NeuroSearch
7.2.7 Trophos
7.2.8 Amarin
7.2.9 Siena Biotech
7.2.10 Sanofi

8 Global Orphan Diseases in CNS Disorders - Strategic Consolidations
8.1 Mergers and Acquisitions
8.1.1 Overview
8.1.2 Major Mergers and Acquisitions Deals
8.1.3 Segmentation by Indication
8.1.4 Segmentation by Geography
8.1.5 Segmentation by Deal Value
8.1.6 Segmentation by Year
8.2 Licensing Agreements
8.2.1 Overview
8.2.2 Major Licensing Deals
8.2.3 Segmentation by Indication
8.2.4 Segmentation by Geography
8.2.5 Segmentation by Deal Value
8.2.6 Segmentation by Year
8.3 Co Development Deals
8.3.1 Segmentation by Geography
8.3.2 Segmentation by Value
8.3.3 Segmentation by Year

9 CNS Orphan Diseases - Appendix
9.1 Market Definition
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.4 Forecasting
9.4.1 Epidemiology-based Forecasting
9.4.2 Expert Panels Validation
9.5 Contact Us
9.6 Disclaimer
9.7 Sources

1.1 List of Tables
Table 1: Orphan Diseases Therapeutics in CNS, Global, Revenue ($m), 2002–2010
Table 2: Orphan Diseases Therapeutics in CNS, Global, Revenue Forecasts ($m), 2010–2017
Table 3: Orphan Diseases Therapeutics in CNS, Global, Revenue Segmentation by Geography, ($m), 2002–2010
Table 4: Orphan Diseases Therapeutics in CNS, Global, Revenue Segmentation by Geography, ($m), 2010–2017
Table 5: Orphan Diseases Therapeutics in CNS, Global, Revenues by Indication ($m), 2002-2010
Table 6: Orphan Diseases Therapeutics in CNS, Global, Revenues by Indication ($m), 2010-2017
Table 7: Orphan Diseases Therapeutics in CNS, The US, Revenues, ($m), 2002–2010
Table 8: Orphan Diseases Therapeutics in CNS, The US, Revenue Forecasts, ($m), 2010–2017
Table 9: Orphan Diseases Therapeutics in CNS, Top Five Countries of Europe, Revenues ($m), 2010–2017
Table 10: Orphan Diseases Therapeutics in CNS, Top Five Countries of Europe, Revenue Forecasts ($m), 2010–2017
Table 11: Orphan Diseases Therapeutics in CNS, Japan, Revenues ($m), 2002–2010
Table 12: Orphan Diseases Therapeutics in CNS, Japan, Revenue Forecasts ($m), 2010–2017
Table 13: ALS Therapeutics, Global, Revenues ($m), 2002–2010
Table 14: ALS Therapeutics, Global, Revenue Forecasts ($m), 2010–2017
Table 15: ALS Therapeutics, Global, Revenue by Geographical Segmentation ($m), 2002–2010
Table 16: ALS Therapeutics, Global, Revenue by Geographical Segmentation ($m), 2010–2017
Table 17: ALS Therapeutics, Global, Annual Cost of Therapy ($), 2002–2010
Table 18: ALS Therapeutics, Global, Annual Cost of Therapy ($m), 2010–2017
Table 19: ALS Therapeutics Market, Global, Generic and Branded Revenues ($m), 2010 and 2017
Table 20: ALS Therapeutics Market, Global, Diseased Population (‘000), 2002–2010
Table 21: ALS Therapeutics Market, Global, Diseased Population (‘000), 2010–2017
Table 22: ALS Therapeutics Market, Global, Treatment Seeking Population (‘000), 2002–2010
Table 23: ALS Therapeutics Market, Global, Treatment Seeking Population (‘000), 2010–2017
Table 24: ALS Therapeutics, Global, Diagnosed Population (‘000), 2002–2010
Table 25: ALS Therapeutics, Global, Diagnosed Population (‘000), 2010-2017
Table 26: ALS Therapeutics, Global, Prescription Population (‘000), 2002–2010
Table 27: ALS Therapeutics, Global, Prescription Population (‘000), 2010–2017
Table 28: HD Therapeutics Market, Global, Revenues ($m), 2002–2010
Table 29: HD Therapeutics Market, Global, Revenue Forecasts ($m), 2010–2017
Table 30: HD Therapeutics, Global, Revenue Segmentation by Country ($m), 2002–2010
Table 31: HD Therapeutics, Global, Revenue Forecasts Segmentation by Country ,($m), 2010–2017
Table 32: HD Therapeutics, Global, Annual Cost of Therapy ($), 2002-2010
Table 33: HD Therapeutics, Global, Annual Cost of Therapy ($), 2010–2017
Table 34: HD Therapeutics Market, Global, Generic and Branded Revenues ($m), 2010 and 2017
Table 35: HD Therapeutics, Global, Diseased Population (‘000), 2002–2010
Table 36: HD Therapeutics, Global, Diseased Population (‘000), 2010–2017
Table 37: HD Therapeutics, Global, Treatment Seeking Population (‘000), 2002–2010
Table 38: HD Therapeutics, Global, Treatment Seeking Population (‘000), 2010–2017
Table 39: HD Therapeutics, Global, Diagnosed Population (‘000), 2002–2010
Table 40: HD Therapeutics, Global, Diagnosed Population (‘000), 2010–2017
Table 41: HD Therapeutics, Global, Prescription Population (‘000), 2002–2010
Table 42: HD Therapeutics, Global, Prescription Population (‘000), 2010–2017
Table 43: MG Therapeutics, Global, Revenues ($m), 2002–2010
Table 44: MG Therapeutics, Global, Revenue Forecasts ($m), 2010–2017
Table 45: MG Therapeutics, Global, Revenue Segmentation by Geography, ($m), 2002–2010
Table 46: MG Therapeutics, Global, Revenue Forecasts Segmentation by Geography, ($m), 2010-2017
Table 47: MG Therapeutics Market, Global, Branded and Generic Revenues ($m), 2010 and 2017
Table 48: MG Therapeutics, Global, Annual Cost of Therapy ($m), 2002–2010
Table 49: MG Therapeutics, Global, Annual Cost of Therapy ($m), 2010–2017
Table 50: MG Therapeutics, Global, Diseased Population (‘000), 2002–2010
Table 51: MG Therapeutics, Global, Diseased Population (‘000), 2010–2017
Table 52: MG Therapeutics, Global, Treatment Seeking Population (‘000), 2002–2010
Table 53: MG Therapeutics, Global, Treatment Seeking Population (‘000), 2010–2017
Table 54: MG Therapeutics, Global, Diagnosed Population (‘000), 2002–2010
Table 55: MG Therapeutics, Global, Diagnosed Population (‘000), 2010–2017
Table 56: MG Therapeutics, Global, Prescription Population (‘000), 2002–2010
Table 57: MG Therapeutics, Global, Prescription Population (‘000), ($m), 2010–2017
Table 58: Other CNS Orphan Disease Therapeutics, Global, Revenues ($m), 2002–2010
Table 59: Other CNS Orphan Disease Therapeutics, Global, Revenue Forecasts ($m), 2010–2017
Table 60: Orphan Diseases Therapeutics in CNS, Global, Discovery Pipeline Molecules, 2011
Table 61: Orphan Diseases Therapeutics in CNS, Global, Pre-clinical Pipeline Molecules, 2011
Table 62: Orphan Diseases Therapeutics in CNS, Global, IND Filed Molecules, 2011
Table 63: Orphan Diseases Therapeutics in CNS, Global, Phase I Pipeline Molecules, 2011
Table 64: Orphan Diseases Therapeutics in CNS, Global, Phase II Pipeline Molecules, 2011
Table 65: Orphan Diseases Therapeutics in CNS, Global, Phase III Pipeline Molecules, 2011
Table 66: Orphan Diseases Therapeutics in CNS, Global, M&A Deal, 2004–2011
Table 67: Orphan Diseases Therapeutics in CNS, Global, Licensing Agreements, by Year, 2004–2012
Table 68: Orphan Diseases Therapeutics in CNS, Global, Co-development Deals by Year, 2009–2011
Table 69: Orphan Diseases Therapeutics in CNS, Global, Co-development Deals by Year, 2009–2011

1.2 List of Figures
Figure 1: Orphan Diseases Therapeutics in CNS, Global, Revenue , ($m), 2002–2017
Figure 2: Orphan Diseases Therapeutics in CNS, Global, Revenue Segmentation by Geography, ($m), 2002–2017
Figure 3: Orphan Diseases Therapeutics in CNS, Global, Branded and Generic Market Share (%), 2010
Figure 4: Orphan Diseases Therapeutics in CNS, Global, Revenue by Indication, ($m) 2002–2017
Figure 5: Orphan Diseases Therapeutics in CNS Market, Drivers and Restraints
Figure 6: Orphan Diseases Therapeutics in CNS, The US, Revenue, ($m), 2002–2017
Figure 7: Orphan Diseases Therapeutics in CNS, Top Five Countries of Europe, Revenues ($m), 2002–2017
Figure 8: Orphan Diseases Therapeutics in CNS, Japan, Revenue ($m), 2002–2017
Figure 9: ALS Therapeutics Market, Global, Revenue ($m), 2002–2017
Figure 10: ALS Therapeutics, Global, Revenue by Geography ($m), 2002–2017
Figure 11: ALS Therapeutics, Global, Annual Cost of Treatment ($m), 2002–2017
Figure 12: ALS Therapeutics Market, Global, Branded and Generic Market Share (%), 2010 and 2017
Figure 13: ALS Therapeutics Market, Global, Diseased Population (Hundreds), 2002–2017
Figure 14: ALS Therapeutics, Global, Treatment Seeking Population (Hundreds), 2002–2017
Figure 15: ALS Therapeutics, Global, Diagnosed Population (Hundreds), 2002–2017
Figure 16: ALS Therapeutics, Global, Prescription Population (Hundreds), 2002–2017
Figure 17: HD Therapeutics Market, Global, Revenues ($m), 2002–2017
Figure 18: HD Therapeutics Market, Global, Revenues by Country ($m), 2002–2017
Figure 19: HD Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2017
Figure 20: HD Therapeutics Market, Global, Branded and Generic Market Share (%), 2010 and 2017
Figure 21: HD Therapeutics, Treatment Algorithm, 2010
Figure 22: HD Therapeutics, Global, Diseased Population (‘000), 2002–2017
Figure 23: HD Therapeutics, Global, Treatment Seeking Population (‘000), 2002–2017
Figure 24: HD Therapeutics, Global, Diagnosed Population (‘000), 2002–2017
Figure 25: HD Therapeutics, Global, Prescription Population (‘000), 2002–2017
Figure 26: MG Therapeutics, Global, Revenues ($m), 2002–2017
Figure 27: MG Therapeutics, Global, Revenues by Country ($m), 2002–2017
Figure 28: MG Therapeutics Market, Global, Branded and Generic Market Share (%), 2010 and 2017
Figure 29: MG Therapeutics, Global, Annual Cost of Therapy ($m), 2002–2017
Figure 30: MG Therapeutics, Treatment Algorithm, 2010
Figure 31: MG Therapeutics, Global, Diseased Population (‘000), 2002–2017
Figure 32: MG Therapeutics, Global, Treatment Seeking Population (‘000), 2002–2017
Figure 33: MG Therapeutics, Global, Diagnosed Population (‘000), 2002–2017
Figure 34: MG Therapeutics, Global, Prescription Population (‘000), 2002–2017
Figure 35: Other Orphan CNS Therapeutics, Global, Revenues ($m), 2002-2017
Figure 36: Orphan Diseases Therapeutics in CNS, Global, R&D Pipeline by Stage of Development (%), 2011
Figure 37: ALS Therapeutics Market, Global, R&D Pipeline by Stage of Development (%), 2011
Figure 38: HD Therapeutics Market, Global, R&D Pipeline by Stage of Development (%), 2011
Figure 39: MG Therapeutics Market, Global, R&D Pipeline by Clinical Stage of Development (%), 2011
Figure 40: Orphan Diseases Therapeutics in CNS, Global, SWOT –Biogen, 2011
Figure 41: Orphan Diseases Therapeutics in CNS, Global, SWOT –Avinar, 2011
Figure 42: Orphan Diseases Therapeutics in CNS, Global, SWOT –Neuraltus, 2011
Figure 43: Orphan Diseases Therapeutics in CNS, Global, SWOT –Cytokinetics, 2011
Figure 44: Orphan Diseases Therapeutics in CNS, Global, SWOT –Avicena, 2011
Figure 45: Orphan Diseases Therapeutics in CNS, Global, SWOT –NeuroSearch, 2011
Figure 46: Orphan Diseases Therapeutics in CNS, Global, SWOT –Trophos, 2011
Figure 47: Orphan Diseases Therapeutics in CNS, Global, SWOT –Amarin, 2011
Figure 48: Orphan Diseases Therapeutics in CNS, Global, SWOT –Siena Biotech, 2011
Figure 49: Orphan Diseases Therapeutics in CNS, Global, SWOT –Sanofi, 2011
Figure 50: Orphan Diseases Therapeutics in CNS, Global, M&As by Indication, 2004–2011
Figure 51: Orphan Diseases Therapeutics in CNS Global, M&As by Geography, 2004–2011
Figure 52: Orphan Diseases Therapeutics in CNS, Global, M&As by Value, 2004–2011
Figure 53: Orphan Diseases Therapeutics in CNS, Global, M&As by Year, 2004–2011
Figure 54: Orphan Diseases Therapeutics in CNS, Global, Licensing Deals by Indication, 2004–2011
Figure 55: Orphan Diseases Therapeutics in CNS, Global, Licensing Deals by Geography, 2004–2011
Figure 56: Orphan Diseases Therapeutics in CNS, Global, Licensing Deals by Value, 2005–2011
Figure 57: Orphan Diseases Therapeutics in CNS, Global, Licensing Deals by Year, 2004–2011
Figure 58: Orphan Diseases Therapeutics in CNS, Global, Co-Developments by Geography, 2004-2011
Figure 59: Orphan Diseases Therapeutics in CNS, Global, Co-Developments by Value, 2005–2011
Figure 60: Orphan Diseases Therapeutics in CNS, Global, Co-Developments by Year, 2005–2011

- Biogen Idec
- Avanir
- Neuraltus
- Cytokinetics
- Avicena
- NeuroSearch
- Trophos
- Amarin
- Siena Biotech
- Sanofi

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology
• The U.S. Orphan Diseases Market Capsule
• Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies
• Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth
• Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
• Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and Weak Pipeline
• Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
• Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
• Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value
• Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth